Sharon Mates, Chairman, President & CEO at Intra-Cellular Therapies, Inc. (ITCI), sold 91,196 shares at $30.39 ($2.8M) on 2020-01-06, disclosed to the SEC on 2020-01-08.
Seasonal sale ($2.8M) by Chairman, President & CEO — this insider has traded ITCI in January in at least three consecutive prior years. Pattern-driven, low signal.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $29.78 | 7,939 | $236K | 8.6% |
| 2 | $29.78 | 7,939 | $236K | 8.6% |
| 3 | $30.39 | 37,659 | $1.1M | 41.4% |
| 4 | $30.39 | 37,659 | $1.1M | 41.4% |
| Total | $30.28 avg | 91,196 | $2.8M | 100% |
| Filing → |
| ITCI | SELL | 2024-08-28 | $14.1M | — | Filing → |
| ITCI | SELL | 2024-08-23 | $18.0M | — | Filing → |
| ITCI | SELL | 2024-03-11 | $8.1M | — | Filing → |